Tuning of redox potentials for the design of ruthenium anticancer drugs -- an electrochemical study of [trans-RuCl(4)L(DMSO)](-) and [trans-RuCl(4)L(2)](-) complexes, where L = imidazole, 1,2,4-triazole, indazole
- PMID: 15500346
- DOI: 10.1021/ic049479c
Tuning of redox potentials for the design of ruthenium anticancer drugs -- an electrochemical study of [trans-RuCl(4)L(DMSO)](-) and [trans-RuCl(4)L(2)](-) complexes, where L = imidazole, 1,2,4-triazole, indazole
Abstract
The electrochemical behavior of [trans-RuCl(4)L(DMSO)](-) (A) and [trans-RuCl(4)L(2)](-) (B) [L = imidazole (Him), 1,2,4-triazole (Htrz), and indazole (Hind)] complexes has been studied in DMF, DMSO, and aqueous media by cyclic voltammetry and controlled potential electrolysis. They exhibit one single-electron Ru(III)/Ru(II) reduction involving, at a sufficiently long time scale, metal dechlorination on solvolysis, as well as, in organic media, one single-electron reversible Ru(III)/Ru(IV) oxidation. The redox potential values are interpreted on the basis of the Lever's parametrization method, and particular forms of this linear expression (that relates the redox potential with the ligand E(L) parameter) are proposed, for the first time, for negatively (1-) charged complexes with the Ru(III/II) redox couple center in aqueous phosphate buffer (pH 7) medium and for complexes with the Ru(III/IV) couple in organic media. The E(L) parameter was estimated for indazole showing that this ligand behaves as a weaker net electron donor than imidazole or triazole. The kinetics of the reductively induced stepwise replacement of chloride by DMF were studied by digital simulation of the cyclic voltammograms, and the obtained rate constants were shown to increase with the net electron donor character (decrease of E(L)) of the neutral ligands (DMSO < indazole < triazole < imidazole) and with the basicity of the ligated azole, factors that destabilize the Ru(II) relative to the Ru(III) form of the complexes. The synthesis and characterization of some novel complexes of the A and B series are also reported, including the X-ray structural analyses of (Ph(3)PCH(2)Ph)[trans-RuCl(4)(Htrz)(DMSO)], [(Ph(3)P)(2)N][trans-RuCl(4)(Htrz)(DMSO)], (H(2)ind)[trans-RuCl(4)(Hind)(DMSO)], and [(Hind)(2)H][trans-RuCl(4)(Hind)(2)].
Similar articles
-
Reactions of potent antitumor complex trans-[Ru(III)Cl4(indazole)2]- with a DNA-relevant nucleobase and thioethers: insight into biological action.Inorg Chem. 2005 Jan 10;44(1):122-32. doi: 10.1021/ic048967h. Inorg Chem. 2005. PMID: 15627368
-
Tuning of redox properties for the design of ruthenium anticancer drugs: part 2. Syntheses, crystal structures, and electrochemistry of potentially antitumor [Ru III/II Cl6-n(Azole)n]z(n = 3, 4, 6) complexes.Inorg Chem. 2005 Sep 19;44(19):6704-16. doi: 10.1021/ic0503737. Inorg Chem. 2005. PMID: 16156629
-
Structure-activity relationships for NAMI-A-type complexes (HL)[trans-RuCl4L(S-dmso)ruthenate(III)] (L = imidazole, indazole, 1,2,4-triazole, 4-amino-1,2,4-triazole, and 1-methyl-1,2,4-triazole): aquation, redox properties, protein binding, and antiproliferative activity.J Med Chem. 2007 May 3;50(9):2185-93. doi: 10.1021/jm061081y. Epub 2007 Apr 3. J Med Chem. 2007. PMID: 17402720
-
Recent developments in ruthenium anticancer drugs.Metallomics. 2009 Nov;1(6):458-70. doi: 10.1039/b904071d. Epub 2009 Aug 13. Metallomics. 2009. PMID: 21305154 Review.
-
Organometallic chemistry, biology and medicine: ruthenium arene anticancer complexes.Chem Commun (Camb). 2005 Oct 14;(38):4764-76. doi: 10.1039/b508531b. Epub 2005 Aug 26. Chem Commun (Camb). 2005. PMID: 16193110 Review.
Cited by
-
Anticancer Potential of Diruthenium Complexes with Bridging Hydrocarbyl Ligands from Bioactive Alkynols.Inorg Chem. 2023 Oct 2;62(39):15875-15890. doi: 10.1021/acs.inorgchem.3c01731. Epub 2023 Sep 15. Inorg Chem. 2023. PMID: 37713240 Free PMC article.
-
Characterization and Evaluation of Bone-Derived Nanoparticles as a Novel pH-Responsive Carrier for Delivery of Doxorubicin into Breast Cancer Cells.Int J Mol Sci. 2020 Sep 14;21(18):6721. doi: 10.3390/ijms21186721. Int J Mol Sci. 2020. PMID: 32937817 Free PMC article.
-
Triiron Complex with N-Ferrocenyl Aminocarbyne Ligand Bridging a Diiron Core: DFT, Electrochemical, and Biological Insights.Inorg Chem. 2024 Jan 15;63(2):1054-1067. doi: 10.1021/acs.inorgchem.3c03408. Epub 2024 Jan 3. Inorg Chem. 2024. PMID: 38166407 Free PMC article.
-
Hypoxia-selective inhibition of angiogenesis development by NAMI-A analogues.Biometals. 2016 Dec;29(6):1035-1046. doi: 10.1007/s10534-016-9974-9. Epub 2016 Nov 3. Biometals. 2016. PMID: 27812766 Free PMC article.
-
Electronic structural investigations of ruthenium compounds and anticancer prodrugs.J Biol Inorg Chem. 2009 Aug;14(6):891-8. doi: 10.1007/s00775-009-0501-0. Epub 2009 Apr 7. J Biol Inorg Chem. 2009. PMID: 19350289
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources